Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
https://doi.org/10.15829/1560-4071-2023-5688
EDN: DIYRXL
Abstract
The novelty of the 2023 National Guidelines for Lipid Metabolism Disorders is presented regarding the categorization of cardiovascular risk, target and optimal levels of blood lipids, diagnosis and therapeutic approaches to the treatment of dyslipidemia.
About the Authors
I. V. Sergienko
E.I. Chazov National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
none
M. V. Ezhov
E.I. Chazov National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
none
References
1. Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) doi:10.15829/1560-4071-2023-5471. EDN YVZOWJ.
2. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.
3. Khan SA, Naz A, Qamar Masood M, Shah R. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. Am J Cardiol. 2020;134:69-73. doi:10.1016/j.amjcard.2020.08.018.
4. Sergienko IV, Ansheles AA, Boytsov SA. Risk factors, lipid profile indicators and hypolipidemic therapy in patients of various categories of cardio-vascular risk: the results of the Aterostop registry. Atherosclerosis and dyslipidemia. 2023;2(51):43-53. (In Russ.) doi:10.34687/2219-8202.JAD.2023.02.0005.
5. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-74. doi:10.1056/NEJMoa1001282.
6. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-61. doi:10.1016/S01406736(05)67667-2.
7. Kim NH, Han KH, Choi J, et al. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019;366:l5125. doi:10.1136/bmj.l5125.
8. Jo SH, Nam H, Lee J, et al. Fenofibrate Use Is Associated With Lower Mortality and Fewer Cardiovascular Events in Patients With Diabetes: Results of 10,114 Patients From the Korean National Health Insurance Service Cohort. Diabetes Care. 2021;44(8):1868-76. doi:10.2337/dc20-1533.
9. Kim KS, Hong S, Han K, Park CY. Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels. Metabolism. 2022;137:155327. doi:10.1016/j.metabol.2022.155327.
10. Sergienko IV, Ansheles AA, Boytsov SA. Mobile application "Aterostop" for a comprehensive assessment of cardiovascular risk in patients in the Russian population. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(4):415-20. (In Russ.) doi:10.26442/00403660.2021.04.200683.
Review
For citations:
Sergienko I.V., Ezhov M.V. Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders. Russian Journal of Cardiology. 2023;28(4S):5688. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5688. EDN: DIYRXL
Views:
1125
Email this article 